Patents Assigned to Lunan Pharmaceutical Group Corporation
-
Patent number: 11795174Abstract: Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.Type: GrantFiled: December 7, 2018Date of Patent: October 24, 2023Assignee: LUNAN PHARMACEUTICAL GROUP CORPORATIONInventors: Runtao Li, Jia Ye, Xin Wang, Zemei Ge, Yingying Liang, Xiaolei Du, Ding Wang, Guimin Zhang, Jingchun Yao, Guifang Zhao
-
Publication number: 20230103858Abstract: The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.Type: ApplicationFiled: March 9, 2021Publication date: April 6, 2023Applicant: Lunan Pharmaceutical Group CorporationInventors: Guimin Zhang, Jingchun Yao, Chenghong Sun, Bin Li, Sina Pan
-
Publication number: 20200369674Abstract: Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.Type: ApplicationFiled: December 7, 2018Publication date: November 26, 2020Applicant: LUNAN PHARMACEUTICAL GROUP CORPORATIONInventors: Runtao LI, Jia YE, Xin WANG, Zemei GE, Yingying LIANG, Xiaolei DU, Ding WANG, Guimin ZHANG, Jingchun YAO, Guifang ZHAO
-
Patent number: 10799521Abstract: The present application relates to a method of icaritin in preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.Type: GrantFiled: December 23, 2019Date of Patent: October 13, 2020Assignee: LUNAN PHARMACEUTICAL GROUP CORPORATIONInventors: Zhiquan Zhao, Jingchun Yao, Xin Li, Yongxia Guan, Guangyan Li
-
Patent number: 10555962Abstract: The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.Type: GrantFiled: October 20, 2014Date of Patent: February 11, 2020Assignee: Lunan Pharmaceutical Group CorporationInventors: Zhiquan Zhao, Jingchun Yao, Xin Li, Yongxia Guan, Guangyan Li
-
Publication number: 20160250243Abstract: The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.Type: ApplicationFiled: October 20, 2014Publication date: September 1, 2016Applicant: Lunan Pharmaceutical Group CorporationInventors: Zhiquan ZHAO, Jingchun YAO, Xin LI, Yongxia GUAN, Guangyan LI
-
Patent number: 8815286Abstract: The present invention provides a pharmaceutical composition comprising the following active ingredients: 1) an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, 2) pioglitazone or a pharmaceutically acceptable salt thereof; and 3) rosuvastatin or a pharmaceutically acceptable salt thereof. The present invention also provides use of the pharmaceutical composition in preparing a medicament for treating hypertension or metabolic syndrome. The pharmaceutical composition of the present invention can treat hypertension or metabolic syndrome, while effectively controlling the incidence of associated cardiovascular diseases and more potently improving survival prognosis in hypertensive patients. When blood pressure is lowered to desired level, the risk factors such as cardiovascular diseases are rectified, metabolic disorders and prognosis of patients are improved, and survival rate of hypertensive patients is raised.Type: GrantFiled: July 23, 2009Date of Patent: August 26, 2014Assignee: Lunan Pharmaceutical Group CorporationInventor: Zhiquan Zhao
-
Patent number: 8722697Abstract: The present invention provides a pharmaceutical composition comprising the following active ingredients: 1) amlodipine or a pharmaceutically acceptable salt thereof, 2) pioglitazone or a pharmaceutically acceptable salt thereof, and 3) rosuvastatin or a pharmaceutically acceptable salt thereof. The present invention also provides use of the pharmaceutical composition in preparing a medicament for treating hypertension or metabolic syndrome. The pharmaceutical composition of the present invention can treat hypertension or metabolic syndrome, while effectively controlling the incidence of associated cardiovascular diseases and more potently improving survival prognosis in hypertensive patients. When blood pressure is lowered to desired level, the risk factors such as cardiovascular diseases are rectified, metabolic disorders and prognosis of patients are improved, and survival rate of hypertensive patients is raised.Type: GrantFiled: July 23, 2009Date of Patent: May 13, 2014Assignee: Lunan Pharmaceutical Group CorporationInventor: Zhiquan Zhao
-
Patent number: 8361965Abstract: A chimeric protein containing neutrophil inhibitory factor and hirugen, the chimeric protein having an amino acid sequence that includes FPRPGSGG (SEQ ID NO:21) Also provided is a pharmaceutical composition comprising the chimeric protein, which can be used for treating or preventing cerebral injury and cerebral edema, or for inhibiting platelet aggregation.Type: GrantFiled: February 18, 2008Date of Patent: January 29, 2013Assignees: Lunan Pharmaceutical Group Corporation, Fagen Biomedical Inc. ChongqingInventors: Kai Fan, Zhiquan Zhao
-
Publication number: 20100150860Abstract: Provided is a chimeric protein comprising neutrophil inhibitory factor, the peptide FRRP specially recognizing the thrombin active site and hirugen. Also provided is a pharmaceutical composition comprising the chimeric protein, which can be used for treating or preventing cerebral injury and cerebral edema, inhibiting platelet aggregation etc.Type: ApplicationFiled: February 18, 2008Publication date: June 17, 2010Applicants: Lunan Pharmaceutical Group Corporation, Fagen Biomedical Inc.Inventors: Kai Fan, Zhiquan Zhao